231 related articles for article (PubMed ID: 35047406)
1. Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment.
Escalona RM; Kannourakis G; Findlay JK; Ahmed N
Front Oncol; 2021; 11():796588. PubMed ID: 35047406
[TBL] [Abstract][Full Text] [Related]
2. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
5. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
6. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
7. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
Figueira RC; Gomes LR; Neto JS; Silva FC; Silva ID; Sogayar MC
BMC Cancer; 2009 Jan; 9():20. PubMed ID: 19144199
[TBL] [Abstract][Full Text] [Related]
8. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.
Ripley D; Tunuguntla R; Susi L; Chegini N
Int J Gynecol Cancer; 2006; 16(5):1794-800. PubMed ID: 17009974
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells.
Gomes LR; Terra LF; Wailemann RA; Labriola L; Sogayar MC
BMC Cancer; 2012 Jan; 12():26. PubMed ID: 22260435
[TBL] [Abstract][Full Text] [Related]
11. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.
Ma DH; Chen JK; Kim WS; Hao YX; Wu HC; Tsai RJ; Hwang DG; Zhang F
Ophthalmic Res; 2001; 33(6):353-62. PubMed ID: 11721189
[TBL] [Abstract][Full Text] [Related]
13. Expression of gelatinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-2 and TIMP-3) in the chicken ovary in relation to follicle development and atresia.
Hrabia A; Wolak D; Kwaśniewska M; Kieronska A; Socha JK; Sechman A
Theriogenology; 2019 Feb; 125():268-276. PubMed ID: 30481606
[TBL] [Abstract][Full Text] [Related]
14. Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes.
Pan CH; Wen CH; Lin CS
Exp Physiol; 2008 May; 93(5):599-612. PubMed ID: 18296491
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.
Knittel T; Mehde M; Grundmann A; Saile B; Scharf JG; Ramadori G
Histochem Cell Biol; 2000 Jun; 113(6):443-53. PubMed ID: 10933221
[TBL] [Abstract][Full Text] [Related]
16. MMPS and TIMPS in ovarian physiology and pathophysiology.
Goldman S; Shalev E
Front Biosci; 2004 Sep; 9():2474-83. PubMed ID: 15353300
[TBL] [Abstract][Full Text] [Related]
17. Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury.
Prakobwong S; Pinlaor S; Yongvanit P; Sithithaworn P; Pairojkul C; Hiraku Y
Int J Parasitol; 2009 Jun; 39(7):825-35. PubMed ID: 19168069
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
Tunuguntla R; Ripley D; Sang QX; Chegini N
Gynecol Oncol; 2003 Jun; 89(3):453-9. PubMed ID: 12798711
[TBL] [Abstract][Full Text] [Related]
19. Correlations Between MMPs and TIMPs Levels in Aqueous Humor from High Myopia and Cataract Patients.
Jia Y; Hu DN; Sun J; Zhou J
Curr Eye Res; 2017 Apr; 42(4):600-603. PubMed ID: 28402202
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
